Publications by authors named "Martina Dicker"

Article Synopsis
  • Immune-related adverse events (irAEs) from immune checkpoint blockade (ICB) therapy affect many cancer patients, with their underlying causes not fully understood.
  • Research identified a bio-active lipid called linoleoyl-lysophosphatidylcholine (LPC 18:2) that may play a key role in modulating these adverse events, with low levels of LPC 18:2 linked to the onset of severe irAEs.
  • Supplementing LPC 18:2 in preclinical and human studies showed a reduction in harmful inflammation and neutrophil levels without detracting from the anti-tumor effectiveness of ICB therapy, suggesting it could enhance patient outcomes.
View Article and Find Full Text PDF

Colitis is characterized by an exacerbated intestinal immune response, but the genetic and other mechanisms regulating immune activation remain incompletely understood. In order to identify new pathways leading to colitis, we sought to identify genes with increased expression in the colons of patients that also are near loci identified by genome wide association studies (GWAS) associated with IBD risk. One such SNP, rs9557195 was of particular interest because it is within an intron of , known to be important for lymphocyte migration.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates the effects of PI3Kδ inhibitor AMG319 in patients with head and neck cancer, showing that it reduces regulatory T cells while boosting the activity of tumor-fighting T cells.
  • However, the treatment resulted in significant immune-related adverse events (irAEs) in nearly half of the patients, raising concerns about systemic effects on T cells.
  • Mouse models suggest that altering dosing regimens could reduce these toxic effects while still effectively shrinking tumors, prompting further exploration of treatment strategies.
View Article and Find Full Text PDF

Inflammatory bowel disease is characterized by an exacerbated intestinal immune response, but the critical mechanisms regulating immune activation remain incompletely understood. We previously reported that the TNF-superfamily molecule TNFSF14 (LIGHT) is required for preventing severe disease in mouse models of colitis. In addition, deletion of lymphotoxin beta receptor (LTβR), which binds LIGHT, also led to aggravated colitis pathogenesis.

View Article and Find Full Text PDF

Plants are attractive hosts for the production of recombinant glycoproteins for therapeutic use. Recent advances in glyco-engineering facilitate the elimination of nonmammalian-type glycosylation and introduction of missing pathways for customized N-glycan formation. However, some therapeutically relevant recombinant glycoproteins exhibit unwanted truncated (paucimannosidic) N-glycans that lack GlcNAc residues at the nonreducing terminal end.

View Article and Find Full Text PDF

IgA nephropathy (IgAN) is a common autoimmune disease that is characterized by formation and deposition of IgA1-containing immune complexes frequently leading to end-stage kidney disease. The IgA1 in these immune complexes carries aberrantly glycosylated O-glycans. In circulating IgA1 these galactose-deficient mucin-type O-glycans are bound by autoantibodies and thus, contribute to immune complex formation and pathogenesis.

View Article and Find Full Text PDF

The production of therapeutic antibodies to combat pathogens and treat diseases, such as cancer is of great interest for the biotechnology industry. The recent development of plant-based expression systems has demonstrated that plants are well-suited for the production of recombinant monoclonal antibodies with defined glycosylation. Compared to immunoglobulin G (IgG), less effort has been undertaken to express immunoglobulin A (IgA), which is the most prevalent antibody class at mucosal sites and a promising candidate for novel recombinant biopharmaceuticals with enhanced anti-tumor activity.

View Article and Find Full Text PDF

Introduction: Glycans are increasingly important in the development of new biopharmaceuticals with optimized efficacy, half-life, and antigenicity. Current expression platforms for recombinant glycoprotein therapeutics typically do not produce homogeneous glycans and frequently display non-human glycans which may cause unwanted side effects. To circumvent these issues, glyco-engineering has been applied to different expression systems including mammalian cells, insect cells, yeast, and plants.

View Article and Find Full Text PDF

Plants are attractive expression hosts for the production of recombinant glycoprotein therapeutics. The quality and efficiency of these biopharmaceuticals are very often influenced by the glycosylation profile. Consequently, approaches are needed that enable the production of recombinant glycoproteins with customized and homogenous N- and O-glycan structures.

View Article and Find Full Text PDF

N-glycosylation of proteins plays an important role in the determination of the fate of newly synthesized glycoproteins in the endoplasmic reticulum (ER). Specific oligosaccharide structures recruit molecular chaperones that promote folding or mannose-binding lectins that assist in the clearance of improperly-folded glycoproteins by delivery to ER-associated degradation (ERAD). In plants, the mechanisms and factors that recognize non-native proteins and sort them to ERAD are poorly understood.

View Article and Find Full Text PDF
Article Synopsis
  • Golgi-resident type-II membrane proteins, likeGnTI, have an uneven distribution in the Golgi stack, but the reasons for this are not well understood.
  • Researchers studied chimeric proteins to analyze how different parts of the GnTI protein influence its location in the cis/medial-Golgi and its interactions with other proteins.
  • The findings indicate that the transmembrane domain of GnTI is crucial for its localization, while its stem region is important for protein complex formation, and a modified version of GnTI that didn't localize properly failed to correct glycosylation issues in plants.
View Article and Find Full Text PDF

Grapevine-shoot extracts (GSE), containing trans-resveratrol and resveratrol oligomers, are commercially available as food supplements. Considering the topoisomerase-targeting properties of trans-resveratrol, the question of whether GSE affect these enzymes, thereby potentially causing DNA damage, was addressed. In a decatenation assay, GSE potently suppressed the catalytic activity of topoisomerase IIα (≥5 μg/mL).

View Article and Find Full Text PDF